Abstract: Embodiments of the present invention generally relate to novel multivalent vaccines and methods of vaccinating. In an embodiment, the present invention is a trivalent vaccine for canine herpesvirus (CHV), canine rotavirus (CRV), and Minute virus of canine (MVC) or other canine parvovirus delivered to pups of a whelp through colostrums and providing sufficient antibody titer to impart protection.

Abstract: The invention relates to antiparasitic compositions comprising a combination of atipamezole or its pharmaceutically acceptable salt and amitraz and their use in a method to control ectoparasite infestations on animals.

Abstract: Embodiments of the present invention generally relate to proteins derived from white spot syndrome virus, nucleic acid sequences encoding them, and their use in the manufacture of a vaccine for prophylaxis and/or treatment of white spot syndrome in crustaceans.

Abstract: Embodiments of the present invention generally relate to novel methods for the treatment and/or prevention of neurological symptoms caused by an avian reovirus, enteric reovirus strain (ERS), and associated characteristics. Other embodiments generally comprise an immunogenic composition or vaccine comprising an ERS for the treatment and/or prevention of neurological symptoms.

Abstract: The present invention relates to hydrophilic Eimeria polypeptides, DNA-fragments encoding those peptides, recombinant DNA molecules comprising such DNA-fragments, live recombinant carriers comprising such DNA-fragments or recombinant DNA molecules and host cells comprising such DNA-fragments, recombinant DNA molecules or live recombinant carriers. Furthermore, the invention relates to antibodies against the polypeptides and to coccidiosis vaccines based upon said polypeptides. The invention also relates to methods for the preparation of such antibodies and vaccines, and to methods for the detection of Eimeria parasites and antibodies against Eimeria parasites.

Abstract: The invention relates to Babesia proteins of a 28kDa protein family and to immunogenic fragments of such proteins, to nucleic acids encoding such proteins or fragments, to cDNA fragments, recombinant DNA molecules, live recombinant carriers, or host cells comprising such nucleic acids, to vaccines, to methods for the preparation of such vaccines, to the use of such proteins or fragments for the prophylactic or therapeutic treatment of an infection or its clinical signs caused by an organism of the family Babesiidae, and to diagnostic tests for detection of nucleic acids, antibodies or antigens of an organism of the family Babesiidae.

Abstract: The present invention relates to the use of a vaccine comprising Clostridium perfringens type C bacterium for protecting swine against Clostridium perfringens type A infection.

Abstract: The present invention relates to a stabiliser composition comprising an amino acid, and a sugar wherein all compounds are chemically defined; to a vaccine composition comprising such a stabiliser composition and a biological molecule and/or a micro-organism; to a method for preparing a pharmaceutical composition comprising admixing such a stabiliser composition with a biological molecule and/or a micro-organism; to the use of such a stabiliser composition, and of vaccines prepared therewith.

Abstract: This invention is directed generally to zilpaterol enantiomer compositions and, in particular, to compositions comprising the 6R,7R zilpaterol enantiomer. This invention is also directed to processes for making such compositions; methods for using such compositions to, for example, increase the rate of weight gain, improve feed efficiency, and/or increase carcass leanness in livestock, poultry, and/or fish; and uses of such compositions to make medicaments. This invention is further directed to methods for determining the absolute configurations of zilpaterol enantiomers.

Abstract: This invention relates to novel Eimeria proteins with immunogenic properties as well as to DNA sequences encoding these proteins. These proteins can be administered to poultry thereby protecting the birds against coccidiosis. In addition the DNA encoding these proteins can be used for the preparation of a vector vaccine against coccidiosis.

Abstract: The present invention relates to the use of an immunogenic dose of immunogenic material of Mycoplasma hyopneumoniae and an immunogenic dose of live attenuated PRRS virus for the manufacture of a vaccine, and to a vaccine kit comprising such a vaccine.

Abstract: Injectable veterinary composition comprising a fluorinated chloramphenicol or thiamphenicol derivative and a solvent system comprising an ether of 1,2-ethanediol oligo- or polymers, and a pyrrolidone solvent.

Abstract: This invention is directed generally to a liquid pharmaceutical composition comprising at least one thyroid hormone (particularly a composition further comprising at least one cyclodextrin compound), a process for making such a composition and a method of using such a composition to treat a condition associated with impaired thyroid hormone function.

Abstract: The present invention relates to nucleic acid sequences encoding a 22.5 kD Streptococcus uberis protein and to parts of such nucleic acid sequences that encode an immunogenic fragment of such proteins, and to DNA fragments, recombinant DNA molecules, live recombinant carriers and host cells comprising such nucleic acid sequences or such parts thereof. The invention also relates to a 22.5 kD Streptococcus uberis protein and immunogenic parts thereof encoded by such sequences. Furthermore, the present invention relates to vaccines comprising such nucleic acid sequences and parts thereof, DNA fragments, recombinant DNA molecules, live recombinant carriers and host cells comprising such nucleic acid sequences or such parts thereof, proteins or immunogenic parts thereof and antibodies against such proteins or immunogenic parts thereof. Also, the invention relates to the use of said proteins in vaccines and for the manufacture of vaccines.

Abstract: It has been found that adequate protection against viral infection in equines can be achieved when vaccination with a live viral vaccine (prime) is followed by vaccination with an inactivated vaccine (boost) for the same virus, wherein the two shots are given no longer than 8 weeks apart. The invention therefore provides a method for vaccination of equines against infection with an equine viral pathogen, wherein an animal is first vaccinated with a (prime) vaccine comprising an attenuated form of the pathogen, followed by a vaccination with a (boost) vaccine comprising the same pathogen in inactivated form, and wherein the boost vaccine is administered no longer than eight weeks after the prime vaccine. The method of the invention is especially useful for vaccination against viral infections such as infections with EIV and/or EHV-1/EHV-4.

Abstract: The invention relates to a needle-less injector having a housing comprising: a chamber defined within said injector for containing liquid to be injected; a liquid outlet for said chamber positioned at the front end of the injector, a dispensing member in contact with the liquid in said chamber and movable in a first direction to reduce the volume of said chamber to cause the liquid contained therein to be expelled through said liquid outlet; drive means for actuating said injector, wherein the dispensing member is a spring-loaded piston movable in said chamber by the spring in the first direction to a preferred position at which the volume of said chamber is at a minimum and the spring is nearly unloaded, and which piston is movable in a second direction opposite to the first direction by actuation of the drive means whilst counteracting a force from the spring and moving the piston to a non-preferred position at which the spring is loaded.

Abstract: The present invention is concerned with vaccinating equines against the equine influenza virus (EIV). It has now been found that adequate protection against equine influenza in equines can be achieved when vaccination with a live equine influenza vaccine (prime) is followed by vaccination with an inactivated influenza vaccine (boost), wherein the two shots are given no longer than 8 weeks apart.

Abstract: Embodiments of the present invention generally provide an inactivated chimeric virus vaccine and/or immunogenic composition for the treatment or prevention of viral infection. Further, various other embodiments of the present invention generally relate to methods of preventing and treating virus infection in such animals with the inactivated vaccine and/or immunogenic composition. Other embodiments comprise methods of preparing a vaccine or immunogenic composition for the treatment or prevention of viral infection in such animals.

Abstract: This invention relates to two attenuated strains of porcine reproductive and respiratory syndrome virus (PRRSV) and immunogenic compositions comprising one or more strains of attenuated porcine reproductive and respiratory syndrome virus (PRRSV).

Abstract: The present invention comprises new pestivirus mutants, characterized in that the mutants are based on a cp strain of the virus wherein part of the gene sequence encoding the Npro region is deleted, except that the deleted part does not encompass the coding sequence for the N-terminal twelve amino acids of the Npro protein. Preferably the pestivirus is the Bovine Viral Diarrhea Virus (BVDV). It was found that a mutant according to the invention is a safe and efficient vaccine candidate.